605033 Shaanxi Meibang Pharmaceutical Group
- 14.41
- +0.18+1.26%
Shaanxi Meibang Pharmaceutical Group News
Meibang Co., Ltd. (605033.SH): Net profit of 444.38 million yuan in the first quarter decreased 35.85% year-on-year
Gelonghui, April 29丨Meibang Co., Ltd. (605033.SH) released its first quarter report. Operating revenue was 312 million yuan, down 9.46% year on year, net profit of 444.38 million yuan, down 35.85% year on year, after deducting non-net profit of 38.39 million yuan, down 43.58% year on year, with basic earnings per share of 0.33 yuan.
Meibang Co., Ltd. (605033.SH) issued 2023 annual results, with net profit of 57.557 million yuan, a year-on-year decrease of 60.33%
Meibang Co., Ltd. (605033.SH) released its 2023 annual report. The company achieved operating income of 6 during the reporting period...
The Recent Pullback Must Have Dismayed Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033) Insiders Who Own 58% of the Company
Key Insights Significant insider control over Shaanxi Meibang Pharmaceutical Group implies vested interests in company growth 53% of the business is held by the top 2 shareholders Using data from
Shaanxi Meibang Pharmaceutical Group Co., Ltd.'s (SHSE:605033) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at Shaanxi Meibang Pharmaceutical Group's (SHSE:605033) recent performance, when its stock has declined 27% over the past three months. But if you pay close a
Meibang Co., Ltd. (605033.SH): 2023 net profit pre-reduced by 55%-64%
Gelonghui, January 29丨Meibang Co., Ltd. (605033.SH) announced the pre-reduction announcement for the 2023 annual results. According to preliminary estimates by the financial department, the company expects to achieve net profit attributable to shareholders of listed companies in 2023 of about 52-65 million yuan. Compared with the same period last year (statutory disclosure data), it will decrease by 80,000-93.09 million yuan, a year-on-year decrease of 55%-64%. In 2023, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be approximately RMB 3604-49.04 million. Compared with the same period last year (statutory disclosure data),
Meibang Co., Ltd. (605033.SH): Received a government subsidy of 14.134,900 yuan
Gelonghui, January 2, 丨 Meibang Co., Ltd. (605033.SH) announced that from January 1, 2023 to December 29, 2023, the company and its subsidiaries and branches received a total of 14.134,900 yuan in government subsidies related to revenue, accounting for 9.7424% of the company's 2022 audited net profit attributable to shareholders of listed companies.
[Instant Analysis of BT Financial Report] Meibang Co., Ltd. 2023 Third Quarter Report: Balance Ratio Decreased, Net Cash Flow Increased Significantly
Announcement time of this financial report: 2023-10-25 17:21:17 Meibang Co., Ltd. (stock code: 605033) is an enterprise focusing on R&D, production, sales and agricultural technology promotion and service of pesticide formulations. Its main products include pesticides, fungicides, plant growth regulators, etc. The company has 25 years of deep experience in the Chinese rural market and has long been committed to promoting agricultural technology and providing services to farmers. As the top 100 sales enterprises in the national pesticide industry and the top 20 domestic pesticide formulation manufacturers, the company has good market competitiveness. According to the 2023 three-quarter report of Meibang Co., Ltd.
Meibang Co., Ltd. (605033.SH) released third-quarter results, with a net loss of 3,419,900 yuan
Meibang Co., Ltd. (605033.SH) released its report for the third quarter of 2023, with the company's operating income of 7748.6...
Meibang Pharmaceutical Earmarks 1.4 Billion Yuan for Factory Construction
Shaanxi Meibang Pharmaceutical Group (SHA:605033) plans to invest 1.38 billion yuan for the construction of a pesticide production line through subsidiary Shaanxi Nuozheng Biotechnology. The plant wil
A wholly-owned subsidiary of Meibang Co., Ltd. (605033.SH) obtained a land use right in Pucheng County to build a pesticide raw drug and intermediate production line with an annual output of 20,000 tons
Meibang Co., Ltd. (605033.SH) announced that on July 4, 2023, Shaanxi Nuozheng Biotech, a wholly-owned subsidiary of the company...
Meibang Co., Ltd. (605033.SH) released first-half results, with net profit of 73.6107 million yuan, a year-on-year decrease of 37.07%
Meibang Co., Ltd. (605033.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Meibang Co., Ltd. (605033.SH): Received an inquiry letter on the review of the application for issuance of convertible bonds
On August 7, 2023, GLONGHUI | Meibang Co., Ltd. (605033.SH) announced that on August 4, 2023, the company received the “Review and Inquiry Letter on Application Documents for Shaanxi Meibang Pharmaceutical Group Co., Ltd. to Issue Convertible Corporate Bonds to Unspecified Targets” (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange). The review agency of the Shanghai Stock Exchange reviewed the application documents submitted by the company to issue convertible corporate bonds to an unspecified target, and formed the first round of inquiries. The company will implement and respond item by item with relevant intermediaries in accordance with the requirements of the inquiry letter. At the same time
Meibang Co., Ltd. (605033.SH): Application to Issue Convertible Bonds Accepted by the Shanghai Stock Exchange
GLONGHUI, July 18丨Meibang Co., Ltd. (605033.SH) announced that on July 18, 2023, the company received the “Notice on Accepting the Application for Issuance of Securities by Shaanxi Meibang Pharmaceutical Group Co., Ltd. Shanghai Main Board Listed Company” issued by the Shanghai Stock Exchange (hereinafter referred to as the “Shanghai Stock Exchange”) (acceptance serial number: Shanghai Stock Exchange (Refinancing) 2023 [] No. 497). The Shanghai Stock Exchange checked the application documents submitted by the company in accordance with relevant regulations., decide It was accepted and examined in accordance with the law
Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033) Is About To Go Ex-Dividend, And It Pays A 1.2% Yield
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033)
Shaanxi Meibang Pharma Unit Buys 35.3 Million Yuan Land For Pesticide and Fertilizer Plant
01:20 AM EST, 12/21/2022 (MT Newswires) -- Shaanxi Thompson Biotechnology, a subsidiary of Shaanxi Meibang Pharmaceutical Group (SHA:605033), purchased land for 35.3 million yuan as part of plans to c
How Much Of Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033) Do Insiders Own?
Every investor in Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companie
We Think That There Are Issues Underlying Shaanxi Meibang Pharmaceutical Group's (SHSE:605033) Earnings
Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders have noticed something concerning in the nu
Smith Barney Stock performance KuaiBao: revenue of 842 million yuan in 2021, net profit increased by nearly 60% over the same period last year.
Smith Barney (605033) disclosed KuaiBao's performance in 2011. during the reporting period, the company achieved operating income of 842 million yuan, an increase of 48.19% over the same period last year, and a net profit of 126 million yuan, an increase of 59.71% over the same period last year.
News flash: Smith Barney shares fell by the daily limit of 19.48 yuan
China Finance Online Co Ltd, January 6 news, today, Smith Barney shares opened at 19.73 yuan, as of 09:39, the stock fell 9.98 percent to 19.48 yuan, sealed the limit. Yesterday (2022-01-05) the net outflow of the stock was-34.9203 million yuan, the main net outflow was-8.1457 million yuan, the net outflow of the single unit was-13.3165 million yuan, and the net outflow of retail investors was-13.4581 million yuan. (for real-time capital flows, please click) in the last month, Smith Barney shares have been on the Dragon and Tiger list for a total of five times, indicating that Smith Barney shares are more active. (
News flash: Smith Barney shares fell by the daily limit of 21.64 yuan
China Finance Online Co Ltd news on January 5, today, Smith Barney shares opened at 24.04 yuan, as of 10:40, the stock fell 9.98 percent to 21.64 yuan, sealed the limit. Yesterday (2022-01-04) the net outflow of the stock was-211 million yuan, the main net outflow was-175 million yuan, the net outflow of the single unit was-15.4927 million yuan, and the net outflow of retail investors was-21.1443 million yuan. (for real-time capital flows, please click.) in the last month, Smith Barney has been on the Dragon and Tiger list for a total of four times, indicating that Smith Barney shares are more active. (more Dragon and Tiger list
Analysis
Price Target
No Data
